Eukaryotic translation initiation factor 4 gamma 3 (EIF4G3) is involved in protein translation within the mammalian mRNA ribosome complex. EIF4G3 has been shown to be a target of cytotoxic T lymphocyte (CTL) produced granzyme B (GrB) suggesting that EIF4G3 may be targeted by CTL cells as a mechanism to inhibit the use of host translational machinery by infectious viruses.
Specificity
Anti-EIF4G3 polyclonal antibody reacts with human, mouse, rat, and bovine eukaryotic translation initiation factor 4 gamma 3 proteins.
Immunogen
Synthetic peptide directed towards the N terminal region of human EIF4G3
application
Anti-EIF4G3 polyclonal antibody is used to tag eukaryotic translation initiation factor 4 gamma 3 proteins for detection and quantitation by Western blotting and in cells and tissues by immunohistochemical (IHC) techniques. It is used as a probe to study the role of eukaryotic translation initiation factor 4 gamma 3 in the initiation of mRNA translation and as a target of CTL cells during infectious virus assault.
Biochem/physiol Actions
EIF4G3 is probable component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5′-terminal secondary structure and recruitment of mRNA to the ribosome. It is thought to be a functional homolog of EIF4G1.
Sequence
Synthetic peptide located within the following region: TAASDQKQEEKPKPDPVLKSPSPVLRLVLSGEKKEQEGQTSETTAIVSIA
Physical form
Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Journal of oncology, 2021, 4936207-4936207 (2021-07-02)
As a selective histone deacetylase (HDAC) inhibitor developed in China, chidamide has been applied for the treatment of refractory peripheral T-cell lymphoma (PTCL) and multiple solid tumors, including lung cancer. However, the underlying mechanisms are not well elucidated. In our
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.